91 9434010495 / 03561 225555

Dr. Amitesh Kumar Chatterjee runs his private clinic ‘Euglycemia’,situated in Jalpaiguri, West Bengal.

Dr. Chatterjee has added on numerous educational achievements to his MBBS qualification. He stood First in First Class in Chemistry (Hons) and a recipient of University Medal. He did his MBBS from Calcutta National Medical College, Kolkata.He passed MRCP (UK) and susequently received MRCPE(Edinburgh), MRCPS (Glasgow) and MRCP (London)... [+]


Appointment Information

09:00AM to 12:00PM
09:00AM to 12:00PM
09:00AM to 12:00PM
09:00AM to 12:00PM
09:00AM to 12:00PM
09:00AM to 12:00PM

'Prafulla Niketan', Race Course Para, Opposite BSNL Tower, Before Fire Brigade Station, Jalpaiguri - 735101, West Bengal

Tel: (03561) 225555


Involved in EDGE study conducted across 27 countries on 45,868 patients worldwide in 2010.
He is one of the principal investigators in FOREFRONT & LANDMARK Trials.
He has presented his original real world study on SAROGLITZAAR,a novel diabetic dyslipidaemic drug at the 77th ADA meetting at San Diego ,Calfornia in 2017.
He has been associated many diabetes research work comprising of various multicentric drug trial.



Published Trials & Studies regarding various anti-diabetic drugs, various case studies in reputed journals.

In 2017, presented at ADA 77th scientific session at San Diego, California, USA with original research work on Saroglitazar.’One-Year Real-Time Clinical Safety and Effectiveness of Saroglitazar in Patients with Diabetic Dyslipidaemia’. (Abstract available in Page-A164, 628-P, (Diabetes, June2017/Volume66/Suppl.1/ADA,77th Scientific session).

Original Research Article:’Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes’.International Journal of Research in Medical Sciences ChatterjeeAK.Int J Res Med Sci.2018 Apr; 6(4):1356-1361

IHJ Cardiovascular Case Reports (CVCR) / (2017)116-118.  (ELSEVIER)

‘Saroglitazar may reduce the requirement of insulin dose during the treatment of diabetic dyslipidaemia’

Presented poster in RSSDI, 45th annual meeting in 2017 on SGLT2 inhibitor science.

Pending publication: ‘Type 2 Diabetes Mellitus and Indian Phenotype-Breaking the Nexus with SGLT2 Inhibitors’ in coming months.

Name acknowledged in the world famous textbook ‘Macleod’s Clinical Examination ‘in the acknowledgements section of the 14th edition.

Published case studies regarding usage of Repaglinide & Saroglaitazar.


Post graduate course in Diabetology (American Diabetes Association- MDRF).
Introduction to Diabetes Care (University of New Castle, Australia).
Advanced course in Diabetes Foot Care (WDF-IDF-DFSI).